1083168-91-5

Basic information

• Product Name: 3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine
• Synonyms: 3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine;5-Chloro-6-methoxypyridine-3-boronic acid pinacol ester;(5-CHLORO-6-METHOXYPYRIDIN-3-YL)BORONIC ACID PINACOL ESTER;Pyridine, 3-chloro-2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
• CAS NO: 1083168-91-5
• Molecular Formula: C₁₂H₁₇BClNO₃
• Molecular Weight: 269.53228
• Mol File: 1083168-91-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine(1083168-91-5)
• EPA Substance Registry System: 3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridine(1083168-91-5)

Safety Data

• Hazardous Substances Data: 1083168-91-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine is used as a pharmaceutical intermediate for the synthesis of various drugs and bioactive molecules. Its unique structural features and reactivity make it a valuable building block in medicinal chemistry, allowing for the development of new therapeutic agents with improved efficacy and selectivity.
As a pharmaceutical intermediate, 3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine can be employed in various applications, such as:
1. Synthesis of Anticancer Agents:
3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]
dioxaborolan-2-yl)-pyridine can be used in the development of anticancer drugs by targeting specific cellular pathways and mechanisms involved in tumor growth and progression. Its unique structural features allow for the design of molecules with high affinity and selectivity for cancer cells, leading to improved therapeutic outcomes.
2. Development of Antimicrobial Agents:
3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine can be utilized in the synthesis of antimicrobial agents to combat drug-resistant bacteria and fungi. Its structural features can be exploited to design molecules with potent antimicrobial activity and low toxicity.
3. Synthesis of Neuroprotective Agents:
3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]
dioxaborolan-2-yl)-pyridine can be used in the development of neuroprotective drugs to treat neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease. Its unique structural features can be employed to design molecules that target specific neuronal pathways and protect against oxidative stress and neuroinflammation.
4. Development of Anti-inflammatory Agents:
3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine can be used in the synthesis of anti-inflammatory drugs to treat various inflammatory conditions, such as arthritis, asthma, and inflammatory bowel disease. Its structural features can be utilized to design molecules with high potency and selectivity for inflammatory mediators and pathways.

Upstream product

• 848366-28-9 5-bromo-3-chloro-2-methoxypyridine 
• 73183-34-3 bis(pinacol)diborane 

Relevant articles and documents

Azaindazole bipyridine derivative myeloid cell proliferation inhibitor as well as preparation method and application thereof in pharmacy

The invention provides an azaindazole bipyridine derivative myeloid cell proliferation inhibitor shown as a formula I, wherein R1, R2 and R3 have the meanings defined in the specification of the invention. A compound in formula I can significantly inhibit proliferation and related disordersof myeloid cells represented by MOLM-16, HL-60, and MV-4-11. The formula I or salt thereof or the related pharmaceutical composition provided by the invention has excellent in-vivo and in-vitro inhibitory activity, good druggability, high bioavailability and no obvious damage to organs. Therefore, the compound shown in the formula I or the salt thereof and the related drug combination have huge clinical application prospects.

Azaindole derivative myelocyte proliferation inhibitor, preparation method thereof, and application of inhibitor in pharmacy

The invention provides an azaindole derivative myeloid proliferation inhibitor as shown in a formula I. In the formula, R1, R2 and R33 are as defined in the specification. The compound shown in the formula I can be used for remarkably inhibiting the proliferation of myeloid cells represented by MOLM-16, HL-60 and MV-4-11 and related diseases of the myeloid cells. The compound shown in the formula I or the salt thereof or the related pharmaceutical composition provided by the invention has excellent in-vivo and in-vitro inhibitory activity, good druggability and high bioavailability, and does not have obvious injury to visceral organs. Therefore, the compound shown in the formula I or the salt thereof and the related pharmaceutical composition have huge clinical application prospects.

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.